Expression of the Receptor for Advanced Glycation End Products, a Target for High Mobility Group Box 1 Protein, and its Role in Chronic Recalcitrant Rhinosinusitis with Nasal Polyps

Archivum Immunologiae et Therapiae Experimentalis

Volumn 63, Issue 3, 2015, Pages 223-230

  Dzaman, Karolina ^a   Szczepanski, Miroslaw J ^a,b   Molinska Glura, Marta ^b   Krzeski, Antoni ^a   Zagor, Mariola ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Chronic inflammation; HMGB1; Innate immunity; Nasal polyposis; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; AGED; CALCINOSIS; CHRONIC DISEASE; DISEASE COURSE; ENDOSCOPY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INNATE IMMUNITY; MALE; METABOLISM; MIDDLE AGED; NASAL POLYPS; NOSE MUCOSA; PATHOLOGY; RECURRENT DISEASE; RHINITIS; SINUSITIS; YOUNG ADULT;

ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGED; CALCINOSIS; CHRONIC DISEASE; DISEASE PROGRESSION; ENDOSCOPY; FEMALE; GENE EXPRESSION REGULATION; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; MALE; MIDDLE AGED; NASAL MUCOSA; NASAL POLYPS; RECURRENCE; RHINITIS; SINUSITIS; YOUNG ADULT;

EID: 84938678239     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-014-0325-7     Document Type: Article

References (33)

1. Andersson U, Erlandsson-Harris H (2004) HMGB1 is a potent trigger of arthritis. J Intern Med 255:344–350
2. Andersson U, Tracey KJ (2004a) HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum Dis Clin North Am 30(3):627–637
3. Andersson UG, Tracey KJ (2004b) HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. J Intern Med 255:318–319
4. Andersson U, Tracey KJ (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29:139–162
5. Bassi R, Giussani P, Anelli V et al (2008) HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J Neurooncol 87:23–33
6. Bellussi LM, Chen L, Chen D et al (2012) The role of high mobility group box 1 chromosomal protein in the pathogenesis of chronic sinusitis and nasal polyposis. Acta Otorhinolaryngol Ital 32:386–392
7. Bellussi LM, Iosif C, Sarafoleanu C et al (2013) Are HMGB1 protein expression and secretion markers of upper airways inflammatory diseases? J Biol Regul Homeost Agents 27:791–804
8. Chen D, Bellussi LM, Passali D et al (2013) LPS may enhance expression and release of HMGB1 in human nasal epithelial cells in vitro. Acta Otorhinolaryngol Ital 33:398–404
9. Chen D, Mao M, Bellussi LM et al (2014) Increase of high mobility group box chromosomal protein 1 in eosinophilic chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 4:453–462
10. Erlandsson Harris H, Andersson U (2004) Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 34:1503–1512
11. Fokkens WJ, Lund VJ, Mullol J et al (2012) EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 50:1–12
12. Gelardi M, Fiorella R, Fiorella ML et al (2009) Nasal-sinus polyposis: clinical-cytological grading and prognostic index of relapse. J Biol Regul Homeost Agents 23:181–188
13. Lund VJ, Kennedy DW (1995) Quantification for staging sinusitis. The Staging and Therapy Group. Ann Otol Rhinol Laryngol Suppl 167:17–21
14. Lund VJ, Kennedy DW (1997) Staging for rhinosinusitis. Otolaryngol Head Neck Surg 117(3 Pt 2):S35–S40
15. Mantell LL, Parrish WR, Ulloa L (2006) Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25:4–11
16. Miszke A, Sanokowska E (1995) Cytology of nasal polyps. Otolaryngol Pol 49:225–230
17. Norlander T, Westrin KM, Fukami M et al (1996) Experimentally induced polyps in the sinus mucosa: a structural analysis of the initial stages. Laryngoscope 106(2 Pt 1):196–203
18. Ostberg T, Kawane K, Nagata S et al (2010) Protective targeting of high mobility group box chromosomal protein 1 in a spontaneous arthritis model. Arthritis Rheum 62:2963–2972
19. Pisetsky DS, Erlandsson-Harris H, Andersson U (2008) High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 10:209
20. Raucci A, Palumbo R, Bianchi ME (2007) HMGB1: a signal of necrosis. Autoimmunity 40:285–289
21. Reh DD, Wang Y, Ramanathan M Jr et al (2010) Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am J Rhinol Allergy 24:105–109
22. Schierbeck H, Lundback P, Palmblad K et al (2011) Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med 17:1039–1044
23. Shim EJ, Chun E, Lee HS et al (2012) The role of high-mobility group box-1 (HMGB1) in the pathogenesis of asthma. Clin Exp Allergy 42:958–965
24. Sims GP, Rowe DC, Rietdijk ST et al (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28:367–388
25. Singh VP, Bali A, Singh N et al (2014) Advanced Glycation end products and diabetic complications. Korean J Physiol Pharmacol 18:1–14
26. Sirois CM, Jin T, Miller AL et al (2013) RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med 210:2447–2463
27. Szczepanski MJ, Czystowska M, Szajnik M et al (2009) Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69:3105–3113
28. Tarchalska-Krynska B, Zawisza E, Samolinski B (1993) Cytograms of nasal mucosa in seasonal and perennial allergic rhinitis. Pneumonol Alergol Pol 61:373–376
29. Ulloa L, Messmer D (2006) High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17:189–201
30. Van Crombruggen K, Holtappels G, De Ruyck N et al (2012) RAGE processing in chronic airway conditions: involvement of Staphylococcus aureus and ECP. J Allergy Clin Immunol 129:1515–1521
31. Van Zele T, Gevaert P, Watelet JB et al (2004) Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol 114:981–983
32. Yang H, Antoine DJ, Andersson U et al (2013) The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 93:865–873
33. Youn JH, Oh YJ, Kim ES et al (2008) High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 180:5067–5074